The report entitled “The US Rosacea Market: Size & Forecasts with Impact Analysis of COVID-19 (2021-2025 Edition)”, provides a detailed analysis of the US rosacea market with market sizing and growth pattern. The analysis includes rosacea market in terms of value, volume and number of patients seeking treatment. The report also provides an overview of the US dermatology drugs market in terms of value and market share by segments.
Furthermore, the report also assesses the key opportunities available in the market and summarizes the dynamic forces that are and will be accountable for growth of the industry. Growth of the US rosacea market has also been forecasted for the period 2020-2024, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.
Vyne Therapeutics (Foamix Pharmaceuticals Ltd.), Galderma, Sol-Gel Technologies Ltd., and Abbvie (Allergan Plc) are some of the major players whose company profiling has been done in the report. This segment of the report summarizes business overview, financial overview and the business strategies adopted by respective companies.
Company Coverage
Executive Summary
The US rosacea market has grown over the past few years and is projected to grow at a high growth rate on the back of rising incidence of disease, and aging population. The growth in the market will be driven by unhealthy eating habits and environmental factors, rising disposable income, ageing population, escalating healthcare expenditure, high prevalence of rosacea, etc. Yet the market growth is restrained by factors such as lack of awareness and knowledge and stringent government regulations for the approval of new drugs.
The COVID-19 pandemic has led to decline in appointments of rosacea patients with dermatologists mainly due to travel restrictions. Thereby, impacting the market growth negatively as far as 2020 is concerned.
Vyne Therapeutics (Foamix Pharmaceuticals Ltd.), Galderma, Sol-Gel Technologies Ltd., and Abbvie (Allergan Plc) are some of the major players whose company profiling has been done in the report. This segment of the report summarizes business overview, financial overview and the business strategies adopted by respective companies.
Company Coverage
- Vyne Therapeutics (Foamix Pharmaceuticals Ltd.)
- Galderma
- Sol-Gel Technologies Ltd.
- Abbvie (Allergan Plc)
Executive Summary
The US rosacea market has grown over the past few years and is projected to grow at a high growth rate on the back of rising incidence of disease, and aging population. The growth in the market will be driven by unhealthy eating habits and environmental factors, rising disposable income, ageing population, escalating healthcare expenditure, high prevalence of rosacea, etc. Yet the market growth is restrained by factors such as lack of awareness and knowledge and stringent government regulations for the approval of new drugs.
The COVID-19 pandemic has led to decline in appointments of rosacea patients with dermatologists mainly due to travel restrictions. Thereby, impacting the market growth negatively as far as 2020 is concerned.
Frequently Asked Questions about the US Rosacea Market
What is the estimated value of the US Rosacea Market?
What is the growth rate of the US Rosacea Market?
What is the forecasted size of the US Rosacea Market?
Who are the key companies in the US Rosacea Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 58 |
| Published | May 2021 |
| Forecast Period | 2021 - 2025 |
| Estimated Market Value ( USD | $ 1106794 Million |
| Forecasted Market Value ( USD | $ 1440503 Million |
| Compound Annual Growth Rate | 6.7% |
| Regions Covered | United States |
| No. of Companies Mentioned | 4 |
Table of Contents
1. Executive Summary
2. Introduction
3. The US Market Analysis
4. Impact of COVID-19
5. Market Dynamics
6. Competitive Landscape
7. Company Profiles
List of Figures
List of Tables
Samples
LOADING...
Companies Mentioned
- Vyne Therapeutics (Foamix Pharmaceuticals Ltd.)
- Galderma
- Sol-Gel Technologies Ltd.
- Abbvie (Allergan Plc)
